CN113995821A - Traditional Chinese medicine composition and preparation for treating novel coronavirus and pneumonia of other viruses and preparation method - Google Patents
Traditional Chinese medicine composition and preparation for treating novel coronavirus and pneumonia of other viruses and preparation method Download PDFInfo
- Publication number
- CN113995821A CN113995821A CN202111248729.7A CN202111248729A CN113995821A CN 113995821 A CN113995821 A CN 113995821A CN 202111248729 A CN202111248729 A CN 202111248729A CN 113995821 A CN113995821 A CN 113995821A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- rhizoma atractylodis
- fried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, a preparation and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following active ingredients in parts by weight: 9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice. The traditional Chinese medicine composition or the traditional Chinese medicine preparation contains various active ingredients such as honeysuckle, white mulberry root-bark, mix-fried ephedra herb and the like, the white mulberry root-bark is used for freeing lung and discharging heat, and the honeysuckle is used for clearing away heat and toxic material and relieving exterior syndrome and expelling pathogenic factors and is a monarch drug; the ephedra stem is used for diffusing lung and relieving asthma, the almond is used for descending the lung and qi, and the lung qi is used as a ministerial drug for regulating qi; rhizoma atractylodis is spicy and fragrant and dries dampness, rhizoma atractylodis macrocephalae strengthens spleen and eliminates dampness, and the common effects of strengthening the middle energizer are ministerial drugs for strengthening spleen, and the Chinese medicinal preparation has obvious treatment effect on various viral pneumonia including novel coronavirus pneumonia.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, a preparation and a preparation method.
Background
Viral pneumonia is an inflammation of the lungs caused by viral infection of the upper respiratory tract, spreading downward. The disease can occur all the year round, but it is common in winter and spring, and it can be fulminating or spreading epidemic. The clinical manifestations are fever, headache, general aching pain, dry cough and lung infiltration. Viral pneumonia occurs in association with the virulence of the virus, the route of infection, as well as the age and immune function status of the host.
At present, the antiviral drugs such as neuraminidase inhibitor and the like are used in the early stage of infection of influenza virus and avian influenza virus, so that the virus can be cleared in time, and pneumonia can be prevented or delayed. The viral pneumonia lacks effective medicine, and western medicine clinical treatment is mainly carried out according to symptoms. Including pneumonia caused by the novel coronavirus which is epidemic in 2020, and specific medicines are also lacking clinically. The traditional Chinese medicine has different technical characteristics for treating viral pneumonia. The traditional Chinese medicine formulates a treatment rule on the basis of determining the core pathogenesis, and has important clinical value for preventing and treating the viral pneumonia by screening effective traditional Chinese medicine combinations for treating the viral pneumonia. Therefore, how to obtain a traditional Chinese medicine composition, a preparation and a preparation method which can effectively treat the novel coronavirus and other viral pneumonia by compounding is a technical problem to be solved at present.
Disclosure of Invention
Therefore, the invention provides a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, a preparation and a preparation method thereof, and aims to solve the problem that the traditional Chinese medicine preparation has poor effect on treating the novel coronavirus and other virus pneumonia.
In order to achieve the above purpose, the invention provides the following technical scheme:
according to the first aspect of the invention, the invention provides a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, which comprises the following active ingredients in parts by weight: 9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice.
Further, the composition comprises the following active ingredients in parts by weight: 12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.
Further, the composition comprises the following active ingredients in parts by weight: 18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.
According to a second aspect of the present invention, the present invention provides a Chinese medicine preparation, which comprises an auxiliary agent and the following active ingredients in parts by weight: 9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice; the auxiliary agent comprises one or more of a filling agent, a binding agent, a disintegrating agent, a lubricating agent, a surfactant and a flavoring agent.
Further, the filler includes one or more of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, and glucose.
Further, the binder comprises one or more of a cellulose derivative, alginate, gelatin, and polyvinylpyrrolidone.
Further, the traditional Chinese medicine preparation comprises the following active ingredients in parts by weight: 12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.
Further, the traditional Chinese medicine preparation comprises the following active ingredients in parts by weight: 18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.
According to a third aspect of the present invention, the present invention provides a method for preparing the above-mentioned Chinese medicinal preparation, comprising the steps of:
s1, putting a plurality of active ingredients into water, heating, decocting, standing, filtering and concentrating to obtain a traditional Chinese medicine liquid;
s2, adding a plurality of auxiliary agents into the traditional Chinese medicine liquid, stirring, and making and forming.
The invention has the following advantages:
the traditional Chinese medicine composition or the traditional Chinese medicine preparation contains various active ingredients such as honeysuckle, white mulberry root-bark, mix-fried ephedra herb and the like, the white mulberry root-bark is used for freeing lung and discharging heat, and the honeysuckle is used for clearing away heat and toxic material and relieving exterior syndrome and expelling pathogenic factors and is a monarch drug; the ephedra stem is used for diffusing lung and relieving asthma, the almond is used for descending the lung and qi, and the lung qi is used as a ministerial drug for regulating qi; rhizoma atractylodis is spicy and dampness-drying, rhizoma atractylodis macrocephalae invigorates the spleen and eliminates dampness, and the common effects of strengthening the middle energizer are ministerial drugs for strengthening the spleen; the radix scrophulariae has the effects of clearing heat and cooling blood, nourishing yin and clearing heat, the lithospermum has the effects of cooling blood and activating blood, and detoxifying and expelling pathogenic factors, and the radix lithospermi and the lithospermum have the effects of assisting the honeysuckle, moistening the clear water, eliminating pathogenic factors and not damaging yin, and are also ministerial drugs; the radix curcumae promotes qi and activates blood circulation, the magnolia officinalis lowers qi and purges the hollow viscera, the magnolia flower dispels wind and unblocks orifices, the monarch and minister drugs are assisted by the radix curcumae, the magnolia officinalis lowers qi and purges bowels, the raw licorice root and the other drugs play a role in treatment, and the radix curcumae, the magnolia officinalis, the magnolia flower and the other drugs have obvious treatment effects on various viral pneumonia including novel coronavirus pneumonia.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The embodiment provides a traditional Chinese medicine composition for treating novel coronavirus and other viral pneumonia, which comprises the following active ingredients in parts by weight:
9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice.
Through repeated epidemic situation practices, the traditional Chinese medicine core pathogenesis of viral pneumonia is gradually realized as epidemic toxin attacking lung, lung qi obstruction, qi activity disorder, spleen dysfunction and blood stasis. Treating viral pneumonia by dispersing lung qi, removing toxic substance, invigorating spleen, regulating qi-flowing, inducing resuscitation and removing blood stasis. Through repeated clinical practice and screening, a hospital-agreed prescription for treating viral pneumonia, namely a Jintong detoxification prescription, is gradually formed, namely the formula of the traditional Chinese medicine composition in the embodiment.
In the traditional Chinese medicine composition of the embodiment, the white mulberry root-bark is used for freeing lung and clearing heat, and the honeysuckle is used for clearing away heat and toxic materials and relieving exterior syndrome and expelling pathogenic factors and is a monarch drug; the ephedra stem is used for diffusing lung and relieving asthma, the almond is used for descending the lung and qi, and the lung qi is used as a ministerial drug for regulating qi; rhizoma atractylodis is spicy and dampness-drying, rhizoma atractylodis macrocephalae invigorates the spleen and eliminates dampness, and the common effects of strengthening the middle energizer are ministerial drugs for strengthening the spleen; the radix scrophulariae has the effects of clearing heat and cooling blood, nourishing yin and clearing heat, the lithospermum has the effects of cooling blood and activating blood, and detoxifying and expelling pathogenic factors, and the radix lithospermi and the lithospermum have the effects of assisting the honeysuckle, moistening the clear water, eliminating pathogenic factors and not damaging yin, and are also ministerial drugs; the radix curcumae has the effects of promoting qi and activating blood, the magnolia officinalis has the effects of depressing qi and clearing hollow viscera, the magnolia officinalis has the effects of dispelling wind and dredging orifices, the monarch and ministerial drugs are assisted by the radix curcumae, the magnolia officinalis has the effects of dispelling wind and dredging orifices, and the raw liquorice has the effect of regulating the functions of the other drugs in the prescription.
Moreover, multiple clinical applications prove that the traditional Chinese medicine composition has a remarkable treatment effect on various viral pneumonia including novel coronavirus pneumonia.
Example 2
The traditional Chinese medicine composition described in example 1 comprises the following active ingredients in parts by weight:
12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.
In the traditional Chinese medicine composition, the ratio of the active ingredients is better than that of the composition in the embodiment 1, after a plurality of patients with viral pneumonia including novel coronavirus pneumonia take the traditional Chinese medicine composition, the effect is more rapid, and the patients can recover to a healthy state in a shorter time.
Example 3
The traditional Chinese medicine composition described in embodiment 2 comprises the following active ingredients in parts by weight:
18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.
The ratio of the active ingredients in the traditional Chinese medicine composition of the embodiment is better than that of the composition in the embodiment 2, compared with the traditional Chinese medicine composition in the embodiment 2, after a plurality of patients with viral pneumonia including novel coronavirus pneumonia take the traditional Chinese medicine composition of the embodiment, the effect is quicker, the patients can recover to a healthy state in a shorter time, and the traditional Chinese medicine composition of the embodiment has a more obvious treatment effect on some patients with severe viral pneumonia.
The traditional Chinese medicine composition in the above embodiments 1-3 can be decocted with water for administration, twice a day, one dose a day, convenient and fast.
Example 4
The embodiment provides a traditional Chinese medicine preparation, which comprises an auxiliary agent and the following active ingredients in parts by weight:
9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice;
the auxiliary agent comprises one or more of a filling agent, a binding agent, a disintegrating agent, a lubricating agent, a surfactant and a flavoring agent.
The traditional Chinese medicine preparation contains the extracts of the active ingredients and various auxiliaries, can be directly taken and is prepared from traditional Chinese medicines and the auxiliaries, can be in various forms such as decoction, pills and tablets, is convenient to carry and take, does not need manual decoction, can be conveniently purchased from a hospital or a pharmacy and then taken, and has better portability.
Example 5
The herbal formulation of embodiment 4, wherein the filler comprises one or more of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, and glucose.
The fillers listed in the embodiment can increase the weight or volume of the tablet, facilitate the forming and cause no adverse reaction to human bodies.
Example 6
The herbal formulation of example 5, wherein the binder comprises one or more of a cellulose derivative, alginate, gelatin, and polyvinylpyrrolidone. Several binders mentioned in this example facilitate the binding of the various components into tablets with good binding stability.
Example 7
The traditional Chinese medicine preparation of embodiment 6, which comprises the following active ingredients in parts by weight:
12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.
In the traditional Chinese medicine preparation of the embodiment, the ratio of the active ingredients is better than that in the embodiment 4, after a plurality of patients with viral pneumonia including novel coronavirus pneumonia take the traditional Chinese medicine composition of the embodiment, the effect is more rapid, and the patients can recover to a healthy state in a shorter time.
Example 8
The traditional Chinese medicine preparation of embodiment 7, which comprises the following active ingredients in parts by weight:
18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.
In the traditional Chinese medicine preparation of the embodiment, the ratio of the active ingredients is better than that in the embodiment 7, after a plurality of patients with viral pneumonia including novel coronavirus pneumonia take the traditional Chinese medicine composition of the embodiment, the effect is quicker, the patients can recover to a healthy state in a shorter time, and the traditional Chinese medicine composition of the embodiment has a more obvious treatment effect on some patients with severe viral pneumonia.
Example 9
This example provides a method of preparing the herbal formulation of any of examples 4-8, comprising the steps of:
s1, putting a plurality of active ingredients into water, heating, decocting, standing, filtering and concentrating to obtain a traditional Chinese medicine liquid;
s2, adding a plurality of auxiliary agents into the traditional Chinese medicine liquid, stirring, and making and forming.
The method for preparing the traditional Chinese medicine preparation in the embodiment can also comprise a drying step after the preparation and the forming, and the preparation of the traditional Chinese medicine preparation in the forms of tablets, pills and the like can be obtained through stirring, preparation and forming and drying. The Chinese medicinal liquid obtained by heating, decocting, standing, filtering and concentrating in step S1 can be directly taken as decoction.
The method for preparing the traditional Chinese medicine preparation is simple, low in cost and easy for industrial mass production.
Test example 1
1. The study included 96 patients, 48 of whom were treated with the herbal formulation of example 8, and 48 of whom were in the placebo group.
2. And (3) inclusion standard:
(1) the pneumonia diagnosis standard person who accords with 'community-acquired pneumonia diagnosis and treatment guideline' of respiratory disease society of Zhonghua medical society in 2015; (2) the clinical diagnosis of viral pneumonia is met: fever with respiratory symptoms, with or without dyspnea (respiratory rate >30 beats/minute); ② the white blood cells are normal or low with or without thrombocytopenia; thoracic imaging (thoracic CT): unilateral or bilateral chest imaging manifested as multiple (at least 2 lesions) or diffusely distributed patchy or frosty glass infiltrates (with or without solid lesions); (3) the disease is developed within 5 days; (4) age 14-75 years, with unlimited genders; (5) written informed consent was approved before the study began (non-behavioral subjects, if the investigator deemed the subjects eligible for their own benefit to participate in the trial, were to be signed with informed consent via their legal guardian and described in the original case history and related documents).
3. Exclusion criteria:
(1) there is clear evidence of bacterial infection, PCT >1 ug/L; (2) treating with other antiviral drugs including antiviral indication Chinese medicinal materials within 1 week before screening; (3) those who meet the diagnosis standard of severe pneumonia in 2015 "guidelines for diagnosis and treatment of community-acquired pneumonia"; (4) chest CT proves that patients with serious pulmonary interstitial diseases, bronchiectasis and other basic pulmonary diseases exist; (5) patients who are positive for streptococcus pneumoniae and legionella pneumophila urine antigens, mycoplasma pneumoniae, chlamydia antibodies; (6) severe liver and kidney dysfunction: ALT and AST exceed the upper limit of normal value by more than 3 times. ② the upper limit of the normal value of creatinine is 1.5 times higher than the normal value; psychotic patients; (7) the disease, either past or present, may affect the patient's participation in the trial or affect the outcome of the study, as judged by the investigator, including: malignant disease, autoimmune disease, liver and kidney diseases, hematopathy, nervous system diseases, and endocrine diseases; (8) present with diseases that severely affect the immune system, such as: human Immunodeficiency Virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.; (9) a history of seizures, or psychiatric conditions that may affect regimen compliance, or a history of abuse of alcohol or illicit drugs; (10) pregnant or lactating women; (11) other investigators considered inappropriate candidates for this trial.
4. Intervention protocol
(1) Sources of drugs
Name of the test drug: the Jintongjiedu decoction particles (the components are the traditional Chinese medicine preparation described in the embodiment 8, the traditional Chinese medicine preparation comprises the following active ingredients, by weight, 18 parts of honeysuckle, 15 parts of white mulberry root-bark, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of magnolia officinalis, 15 parts of figwort root, 9 parts of turmeric root-tuber, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of white atractylodes rhizome, 15 parts of lithospermum and 6 parts of raw licorice, the characteristics are that the product is brown yellow to brown particles, the taste is slightly bitter, the smell is slightly fragrant, and the specification is that 6g of the product is packed in a bag.
Placebo: jintong detoxification prescription granule simulant (the simulant is completely consistent with the test medicine in the aspects of color, specification, package, label, content shape, etc.)
(2) Treatment regimens
In addition to the study drugs, specific therapeutic drugs are referred to the "guidelines for diagnosis and treatment of community-acquired pneumonia" 2015 edition of respiratory disease of the Chinese medical society. Firstly, antiviral western medicines and traditional Chinese medicines for resisting virus indications such as Xiyanping, pyretic toxicity relieving, phlegm heat clearing, golden flower refreshing feeling and radix isatidis cannot be used in principle within one week before the study and after the study enters a random grouping period; secondly, when the used antibiotics, hormones, antipyretic analgesic, cough and asthma relieving and other symptomatic treatment medicines are treated, the medicine name, the dosage, the use times and the duration must be strictly recorded in a case report table; during the research period, the name, the dosage, the use times and the duration of the medicine which needs to be taken for other diseases are recorded in a case report table; fourthly, receiving the drug therapy for better controlling the hypertension, the angina, the diabetes or other diseases. The course of medication in this study was 7 days, and subjects were evaluated for compliance and adverse drug reactions were recorded.
5. Clinical observation endpoints and indices
(1) The main effectiveness indexes are as follows:
rate of remission of clinical symptoms.
(2) Secondary effectiveness index:
restoring the normal proportion of the blood oxygen saturation; secondly, the time for relieving single symptoms such as fever, cough, expectoration and the like; the hospitalization time; fourthly, the time of aggravation (transferring to RICU); incidence rate of pneumonia complications; and sixthly, the combined utilization rate of antibiotics.
(3) The safety index is as follows:
firstly, evaluating adverse events; clinical laboratory indexes: routine blood, urine and stool, and biochemical serum (CK, ALT, AST, Bun, Cr); ③ 12 leads electrocardiogram; and fourthly, checking the physique.
(4) Criteria for therapeutic effect
Refer to the standard of the people's republic of China, the standard of curative effect of Chinese medicine disease diagnosis, and the guidelines of clinical research on new Chinese medicines (trial implementation).
The clinical symptom scores for the remission (%) of clinical symptoms for the two groups of subjects are shown in table 1 below:
TABLE 1
(5) Results of the study
The study used the total integrated remission of clinical symptoms as the primary observation. After 7 days of treatment, the clinical symptom relief rate of the treatment group is better than that of the control group, and the treatment group has statistical significance (P < 0.001).
The clinical symptom relief rate of 7 days of the Jintong detoxification prescription study is shown in the table 2:
table 2:
note 1: clinical symptom remission rate (%) - (pre-treatment clinical symptom score-treatment 7-day clinical symptom score)/pre-treatment score × 100%.
Note 2: statistical analysis was performed after LOCF principle of treatment for 7 days with missing clinical symptom scores.
Wilcoxon rank sum test
6. Conclusion of the study
The results of the intervention study of the Jintong detoxification prescription on the viral pneumonia show that the clinical symptom relief rate of the test group is better than that of the control group (P < 0.05). The Jintong detoxification prescription is suggested to have better clinical curative effect on treating viral pneumonia (because the test example selects lighter patients, the patients in the control group have certain self-healing effect).
Test example 2
Viral pneumonia typical case 1: -H7N 9 avian influenza pneumonia
For some women, 41 years old, the primary cause of "general malaise 7 days, high fever, cough 5 days" was admitted to the hospital in 2017, 4 months and 14 days. 7 days in the course of disease, weakness at the beginning of the disease, malaise all over the body, 5 days of high fever, 40 ℃, accompanied with myalgia, headache, cough, yellow phlegm cough and suffocating, CT of the chest of the hospital shows: right lung pneumonia, poor curative effect in the hospital. The medical history of pursuing questions: poultry (chickens) died of illness were contacted before illness; and was in intimate contact with the mother 2 weeks ago, and his mother died from "pneumonia" 1 week ago. Admission to the examinee: t36.7 ℃, P76 times/min, R25 times/min, BP103/67 mmHg. The traditional Chinese medicine composition has the advantages of clearing mind, promoting respiration, acute disease, throat congestion, clear sound in double lung percussion, weak breath sound in double lower lungs, moist rale of right lower lung, and no abnormality in heart and abdomen. Testing after admission: blood gas (not inhaled oxygen) PO26.74Kpa. Blood normal WBC3.30 × 109/L, LY% 20.90%, NE% 74.61%. CRP80mg/L, PCT0.73ng/ml, ESR40.0 mm/h. Liver function ALT215.7U/L, AST122.3U/L, ALB37.2g/L, GGT231.9U/L. Influenza a universal nucleic acid: and (4) positive. Market CDC: pharynx swab, sputum H7N9 nucleic acid positive. Chest CT: inflammation of both lungs and inflammation of both lower lobes. And (3) diagnosis: human is infected with H7N9 avian influenza virus pneumonia. The traditional Chinese medicine decoction prepared from the traditional Chinese medicine composition in the embodiment 5 is administered for dispersing lung qi, detoxifying, invigorating spleen, regulating qi, dredging orifices and dissipating blood stasis. After 1 week of treatment, the patients have better condition than before, no obvious suffocation, cough relief, occasional phlegm, blood in phlegm, appetite, 1-2 times of defecation without dryness, gradually reduced oxygenation condition, pale and swollen tongue, white and greasy fur, peeled tongue root and tongue fur, yellowish and mild pulse condition.
Test example 3
Viral pneumonia typical case 2: -influenza virus pneumonia
Patient Jin A certain, male, 56 years old. Fever is not caused by obvious inducement in 1 month in 2018, the body temperature is 40 ℃ at most, the fever is accompanied by chilliness, shivering, muscular soreness of the whole body, headache, hypodynamia, nasal obstruction and running nose, cough, yellow white sticky phlegm and difficult cough, the body temperature can be reduced to normal by oral medication in community hospitals, the cough is not relieved, suffocation occurs, the weight is obviously increased after activity, the patient is diagnosed in the outpatient service of the great-rise hospital in 1 month and 13 days, and the chest CT examination prompt: the diploponic exudative inflammation considers lung infection, the influenza A antigen is checked to be positive in hospital within 1 month and 14 days, oseltamivir is used for resisting virus, cefoxitin sodium, levofloxacin and moxifloxacin are used for resisting infection, suffocation of a patient is not relieved, chest X-ray is rechecked within 1 month and 17 days, diploponic exudative lesions are obviously aggravated, a reinforcer 80mg BID is added within 1 month and 18 days, the rechecking chest imaging is improved, but the suffocation of the patient is not relieved, and the checking of blood gas prompts the type I respiratory failure. 2018-1-24 days, after 10 weeks of treatment, the patient's condition is obviously improved, no obvious breath holding, cough relieving, occasional phlegm, appetite stimulating, 1-2 days of defecation, pale tongue with yellowish fur and rapid pulse.
Test example 4
Viral pneumonia typical case 3: -novel coronavirus pneumonia
The patient aged a certain person, male, 57 years old, and Zhangkou in Hebei. Cough expectoration, no fever, no asthma, no abdominal pain, no diarrhea, no nausea and no vomiting appear in 2 months in 2020, the result of the nucleic acid detection of the new coronavirus from the Korean CDC throat swab is positive, 2020-2-25 is sent to a three-room fixed-point hospital, 2020-2-26 is used for routine blood-checking: WBC 3.6X 109/L, N45.1%, L1.3X 109/L, EOS 0.8X 109/L, CRP 8.0 mg/L. ALT 18U/L, GLU 6.08mmol/L, BUN 4.3mmol/L, Cr 76umol/L, K3.62 mmol/L, no obvious abnormality was found in blood coagulation related examination, chest CT showed: 1. the right superior pulmonary lobe bullae; 2. inflammation of the right middle lung lobe; 3. old lesions are frequently generated on the posterior segment and lower lobe of the upper lobe of the right lung; 4. the right pleura was slightly thickened and was confirmed to be pneumonia (common type) infected with a novel coronavirus. The traditional Chinese medicine decoction prepared from the traditional Chinese medicine composition in the embodiment 5 is administered for dispersing lung qi, detoxifying, invigorating spleen, regulating qi, dredging orifices and dissipating blood stasis. After 2 weeks of treatment. The symptoms of the patients are obviously improved, and no complaints are caused. Chest CT suggests that the contrast of the density image of the lobe mill glass in the right lung of 2-28 is greatly absorbed, the range of the real change image is slightly reduced, the new corona nucleic acid is negative twice continuously, and then the image is improved and discharged.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (9)
1. A traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia is characterized by comprising the following active ingredients in parts by weight:
9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice.
2. The traditional Chinese medicine composition according to claim 1, which comprises the following active ingredients in parts by weight:
12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.
3. The traditional Chinese medicine composition according to claim 2, which comprises the following active ingredients in parts by weight:
18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.
4. The traditional Chinese medicine preparation is characterized by comprising an auxiliary agent and the following active ingredients in parts by weight:
9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice;
the auxiliary agent comprises one or more of a filling agent, a binding agent, a disintegrating agent, a lubricating agent, a surfactant and a flavoring agent.
5. The Chinese medicinal formulation of claim 4, wherein the filler comprises one or more of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, and glucose.
6. The herbal formulation of claim 5, wherein the binding agent comprises one or more of a cellulose derivative, alginate, gelatin, and polyvinylpyrrolidone.
7. The traditional Chinese medicine preparation according to claim 6, which comprises the following active ingredients in parts by weight:
12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.
8. The traditional Chinese medicine preparation according to claim 7, which comprises the following active ingredients in parts by weight:
18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.
9. A method of preparing the Chinese medicinal formulation of any one of claims 4 to 8, comprising the steps of:
s1, putting a plurality of active ingredients into water, heating, decocting, standing, filtering and concentrating to obtain a traditional Chinese medicine liquid;
s2, adding a plurality of auxiliary agents into the traditional Chinese medicine liquid, stirring, and making and forming.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111248729.7A CN113995821B (en) | 2021-10-26 | 2021-10-26 | Chinese medicinal composition for treating pneumonia caused by novel coronavirus and other viruses, preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111248729.7A CN113995821B (en) | 2021-10-26 | 2021-10-26 | Chinese medicinal composition for treating pneumonia caused by novel coronavirus and other viruses, preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113995821A true CN113995821A (en) | 2022-02-01 |
| CN113995821B CN113995821B (en) | 2023-03-28 |
Family
ID=79924160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111248729.7A Active CN113995821B (en) | 2021-10-26 | 2021-10-26 | Chinese medicinal composition for treating pneumonia caused by novel coronavirus and other viruses, preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113995821B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306529A (en) * | 2022-01-20 | 2022-04-12 | 石家庄市人民医院 | Traditional Chinese medicine composition for convalescent period of new coronary pneumonia and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111265586A (en) * | 2020-03-16 | 2020-06-12 | 首都医科大学附属北京地坛医院 | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof |
| CN111407862A (en) * | 2020-05-27 | 2020-07-14 | 石家庄市中医院 | Lung-clearing traditional Chinese medicine composition containing flos phragmitis and preparation method of lung-clearing traditional Chinese medicine composition |
| CN111514230A (en) * | 2020-05-18 | 2020-08-11 | 湖南康寿制药有限公司 | Lung-ventilating and lung-ventilating traditional Chinese medicine capsule containing ephedra and apricot seeds and preparation method of lung-ventilating and lung-ventilating traditional Chinese medicine capsule |
-
2021
- 2021-10-26 CN CN202111248729.7A patent/CN113995821B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111265586A (en) * | 2020-03-16 | 2020-06-12 | 首都医科大学附属北京地坛医院 | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof |
| CN111514230A (en) * | 2020-05-18 | 2020-08-11 | 湖南康寿制药有限公司 | Lung-ventilating and lung-ventilating traditional Chinese medicine capsule containing ephedra and apricot seeds and preparation method of lung-ventilating and lung-ventilating traditional Chinese medicine capsule |
| CN111407862A (en) * | 2020-05-27 | 2020-07-14 | 石家庄市中医院 | Lung-clearing traditional Chinese medicine composition containing flos phragmitis and preparation method of lung-clearing traditional Chinese medicine composition |
Non-Patent Citations (4)
| Title |
|---|
| 万力生: "《中医适宜技术在儿科疾病中的应用》", 30 April 2017 * |
| 何胜荣等: "新冠肺炎中药临床研究的伦理审查挑战", 《医学与哲学》 * |
| 卫生健康为 中医药局: "关于印发新型冠状病毒感染的肺炎诊疗方案（试行第三版）的通知", 《HTTP://WWW.GOV.CN/ZHENGCE/ZHENGCEKU/2020-01/23/CONTENT_5471832.HTM》 * |
| 黄楚栓等: "基于中医传承辅助平台探讨治疗老年社区获得性肺炎方剂的组方规律", 《广州中医药大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306529A (en) * | 2022-01-20 | 2022-04-12 | 石家庄市人民医院 | Traditional Chinese medicine composition for convalescent period of new coronary pneumonia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113995821B (en) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100358549C (en) | Diarrhea treating chinese medicine composition | |
| CN112353855A (en) | Application of traditional Chinese medicine composition in preparation of medicine for adjuvant therapy of novel coronavirus pneumonia | |
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN111671867B (en) | Novel traditional Chinese medicine composition for treating mild coronary virus pneumonia cough | |
| CN113995821B (en) | Chinese medicinal composition for treating pneumonia caused by novel coronavirus and other viruses, preparation and preparation method thereof | |
| WO2006094460A1 (en) | A medicine for treating cough and asthma and preparation method thereof | |
| CN104324125B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| CN116139237A (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN114632129B (en) | Traditional Chinese medicine for treating pediatric cough variant asthma and preparation method thereof | |
| CN114224998B (en) | Traditional Chinese medicine composition, preparation and application for treating spleen-kidney yang deficiency type functional dyspepsia | |
| CN113577187B (en) | Traditional Chinese medicine composition and traditional Chinese medicine extract for treating influenza and preparation method and application thereof | |
| CN114558049A (en) | Traditional Chinese medicine prescription for treating Chronic Obstructive Pulmonary Disease (COPD) stable phase series and application | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN101693077B (en) | Medicament for treating febrile bronchial asthma and chronic bronchitis | |
| CN114470110B (en) | Anti-rhinitis traditional Chinese medicine composition with pain relieving effect | |
| CN115624586B (en) | Traditional Chinese medicine composition for treating hormone-dependent asthma and application thereof | |
| CN110538280A (en) | antidepressant confirmed by pharmacological activity and preparation method thereof | |
| CN114732889B (en) | Traditional Chinese medicine composition and traditional Chinese medicine oral preparation for treating phlegm turbidity and lung obstruction in acute attack stage of bronchial asthma | |
| CN115607644B (en) | Traditional Chinese medicine composition for treating IgA nephropathy and preparation method thereof | |
| CN103041160B (en) | Traditional Chinese medicine composition for curing acute pharyngitis and preparation method thereof | |
| CN106309901A (en) | Radix scrophulariae buccal tablets and preparation method thereof | |
| CN114949147A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis as well as preparation method and application thereof | |
| CN115531503A (en) | External traditional Chinese medicine composition for rehabilitation period of novel coronavirus pneumonia, acupoint plaster, preparation method and application | |
| CN117205258A (en) | Traditional Chinese medicine composition for preventing and treating liver injury as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |